Celularity Inc. last reported quarterly results on May 9, 2025, for Q1 FY2025 (the quarter ended Mar 31, 2025): revenue of $11.4 million (-22.2% year over year) and diluted EPS of -$0.84. It usually reports 9–51 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–51 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
11
-22.2%
|
-20
+10.3%
|
-0.84
+18.4%
|
|
Oct 25, 2024
25 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
9
+145.5%
|
-16
+82.9%
|
-0.73
+85.3%
|
|
May 21, 2024
51 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Jan 9, 2024
9 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
|
Nov 10, 2022
41 days after quarter end
|
—
ended Sep 30, 2022
|
—
|
—
|
—
|
|
Aug 10, 2022
41 days after quarter end
|
—
ended Jun 30, 2022
|
—
|
—
|
—
|
|
May 16, 2022
46 days after quarter end
|
—
ended Mar 31, 2022
|
—
|
—
|
—
|
|
Nov 12, 2021
43 days after quarter end
|
—
ended Sep 30, 2021
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CELU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1752828
- Former names
- GX Acquisition Corp. (until Jul 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.